Krebs Biochemicals closes trading window until Q1 results

1 min read Updated on 23 Jun 2026, 04:21 AM

Reviewed by

Jubin VScanX News Team

AI Summary

Krebs Biochemicals & Industries Ltd has closed its trading window for designated insiders effective from the close of business hours on June 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The restriction applies to promoters, directors, designated persons, and their immediate relatives, with the Board meeting date to be intimated later.

*this image is generated using AI for illustrative purposes only.

Krebs Biochemicals & Industries Ltd has closed its trading window for designated insiders effective immediately, restricting dealings in the company's securities until the financial results for the first quarter are made public. The closure, effective from the close of business hours on June 30, 2026, is mandated by the SEBI (Prohibition of Insider Trading) Regulations, 2015 and will remain in force until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026.

The restriction applies to promoters, directors, designated persons, their immediate relatives, and all connected persons covered under the company's code of conduct. This measure ensures that no insider trading occurs while material non-public information regarding the quarterly performance is pending disclosure.

Board Meeting Schedule

The company stated that the specific date for the Board meeting to consider the unaudited financial results for the first quarter will be intimated to the stock exchanges in due course. The filing was submitted to BSE Limited and National Stock Exchange of India Ltd on June 22, 2026.

Key Details

Event	Date/Time
Trading window closure	June 30, 2026 (close of business hours)
Quarter end	June 30, 2026
Trading window reopens	48 hours after results declaration

Historical Stock Returns for Krebs Biochemicals & Industries

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.25%	-8.13%	-7.72%	-12.96%	-31.51%	-48.96%

What market expectations are investors setting for Krebs Biochemicals' Q1 performance given the early trading window closure?

How might the timing of the unaudited financial results announcement influence the stock's volatility in the coming weeks?

Could the closure of the trading window signal potential strategic shifts or significant changes in the company's financial health?

Financial Performance

Revenue from operations for the year ended March 31, 2026, stood at ₹2,575.79 lacs, a significant decrease from ₹4,402.08 lacs in the prior year. For the quarter ended March 31, 2026, revenue was recorded at ₹881.27 lacs. Total income for the year was ₹2,575.79 lacs, down from ₹4,402.08 lacs in FY25.

The company's total expenses for FY26 amounted to ₹4,269.10 lacs. Key expense components included finance costs of ₹708.59 lacs and employee benefits expenses of ₹1,038.80 lacs. Depreciation and amortisation expenses were reported at ₹642.33 lacs for the year.

Key Metrics

The board approved the financial results at its meeting held on May 21, 2026. The statutory auditors issued an unmodified report on the financial statements.

Metric	FY26 (₹ in lacs)	FY25 (₹ in lacs)
Revenue from Operations	2,575.79	4,402.08
Total Income	2,575.79	4,402.08
Total Expenses	4,269.10	7,094.48
Net Profit/(Loss)	(1,693.31)	(2,693.93)
Earnings Per Share (Basic)	(7.85)	(12.49)

Operational Status

The company noted that its Vizag manufacturing unit has remained closed following an order from the Andhra Pradesh Pollution Control Board dated February 7, 2025. Management stated that it is in constant dialogue with the authorities regarding the revocation of the closure order.

As of March 31, 2026, the company reported a negative net worth of ₹16,275.47 lacs. The debt-equity ratio was recorded at (1.38) times. The company's cash and cash equivalents decreased to ₹12.91 lacs from ₹14.16 lacs at the end of the previous year.

Historical Stock Returns for Krebs Biochemicals & Industries

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.25%	-8.13%	-7.72%	-12.96%	-31.51%	-48.96%

What specific remediation steps is Krebs Biochemicals undertaking to satisfy the Andhra Pradesh Pollution Control Board's requirements, and what is the realistic timeline for reopening the Vizag manufacturing unit?

Given the company's deeply negative net worth of ₹16,275.47 lacs and dwindling cash reserves, what debt restructuring or capital infusion strategies is management exploring to avoid insolvency proceedings?

How might the prolonged closure of the Vizag plant impact Krebs Biochemicals' key customer relationships and market share in the biochemicals sector, and can these be recovered once operations resume?